Park Place Capital Corp Viking Therapeutics, Inc. Transaction History
Park Place Capital Corp
- $319 Million
- Q3 2024
A detailed history of Park Place Capital Corp transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Park Place Capital Corp holds 9 shares of VKTX stock, worth $645. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9Holding current value
$645% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
460Shares Held
65.6MCall Options Held
6.24MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$724 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$432 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$368 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$162 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$133 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.5B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...